Lusupultide is a genetically engineered surfactant preparation containing recombinant surfactant protein C (rSP-C) embedded in a phospholipid matrix. It reduces surface tension and keeps the alveoli open, thus ensuring a stable surface for oxygen passage. Lusupultide had got orphan designations from EMA for the treatment of acute respiratory distress syndrome and aspiration pneumonitis requiring intubation and mechanical ventilation. Lusupultide development has been discontinued.